glp-1/gip/glucagon triple agonist retatrutide glp-1 gip glucagon phase 3 2025 Dual and Triple Gut Peptide Agonists Discovery of a potent and

In first protocol, the male mice were deprived of food from 18:00 (16 h fasting) with free access to water 1 day before the experiment

10 In particular, semaglutide was most successful at reducing alanine transaminase (mean difference, 14.70 U/L), aspartate transaminase (mean difference, 9.32 U/L), g-glutamyl transferase (mean difference, 16.56 U/L), and liver stif fness measurement (mean difference, 3.08 kPa) compared with the other medications studied, whereas liraglutide demonstrated efficacy in reducing subcutaneous adipose tissue (mean difference, 30.27 cm 2 ) and liver fat fraction (mean difference, 5.16%)

53 Another GIP/GLP-1/GCG triple RA, LY3437943, has also undergone Phase I trials

insulin dose at GLP-1RA initiation was only decreased if HbA1c was below 7.5% (60)